FLAURA2中国人群亚组总生存期分析显示,该联合方案获益-风险特征与全球队列一致 研究结果进一步证实了泰瑞沙联合化疗可作为中国EGFR突变晚期非小细胞肺癌患者的一线治疗选择 济南2026年9月18日 /美通社/ -- 在第二十九届全国临床肿瘤学大会暨2026年CSCO学术年会期间,阿斯利康的泰瑞沙®(英文商品名:TAGRISSO®,通用名:甲磺酸奥希替尼片,以下简称 "奥希替尼")发布了全球...
Source LinkFLAURA2中国人群亚组总生存期分析显示,该联合方案获益-风险特征与全球队列一致 研究结果进一步证实了泰瑞沙联合化疗可作为中国EGFR突变晚期非小细胞肺癌患者的一线治疗选择 济南2026年9月18日 /美通社/ -- 在第二十九届全国临床肿瘤学大会暨2026年CSCO学术年会期间,阿斯利康的泰瑞沙®(英文商品名:TAGRISSO®,通用名:甲磺酸奥希替尼片,以下简称 "奥希替尼")发布了全球...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.